<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40702808</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1940-4034</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><PubDate><Year>2025</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Journal of cardiovascular pharmacology and therapeutics</Title><ISOAbbreviation>J Cardiovasc Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment.</ArticleTitle><Pagination><StartPage>10742484251361059</StartPage><MedlinePgn>10742484251361059</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/10742484251361059</ELocationID><Abstract><AbstractText>BackgroundWhile PCSK9 inhibition has proven safe and effective, there is limited research on using intravascular ultrasound (IVUS) to assess the impact of atorvastatin combined with PCSK9 inhibitors on borderline coronary lesions.MethodsFrom June 2022 to June 2025, a detailed analysis of biochemical markers, coronary angiography (CAG), and IVUS was conducted on 69 patients with borderline coronary lesions after different treatments.ResultsOf the 69 patients enrolled, 60 completed the 48-week study. All groups showed significant low-density lipoprotein cholesterol (LDL-C) reductions, with Group C (Alirocumab&#x2009;+&#x2009;Atorvastatin) having the largest decrease from 3.64 to 1.48 (<i>P</i>&#x2009;&lt;&#x2009;.001). At 48 weeks, arterial lumen volumes increased in all groups, but Group C's was significantly larger than Groups A (Alirocumab&#x2009;+&#x2009;placebo) and B (Atorvastatin&#x2009;+&#x2009;placebo) (<i>P</i>&#x2009;=&#x2009;.038). Group C also had a greater reduction in plaque volume compared to Groups A and B (<i>P</i>&#x2009;=&#x2009;.041).ConclusionAlirocumab and Atorvastatin together significantly lowered LDL-C levels and improved the vascular environment, notably reversing plaque in patients with borderline coronary lesions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zeyu</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0006-8105-8803</Identifier><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiovasc Pharmacol Ther</MedlineTA><NlmUniqueID>9602617</NlmUniqueID><ISSNLinking>1074-2484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>A0JWA85V8F</RegistryNumber><NameOfSubstance UI="D000069059">Atorvastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091362">PCSK9 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069059" MajorTopicYN="Y">Atorvastatin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018084" MajorTopicYN="Y">Ultrasonography, Interventional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="Y">Cholesterol, LDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091362" MajorTopicYN="Y">PCSK9 Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058226" MajorTopicYN="Y">Plaque, Atherosclerotic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003331" MajorTopicYN="Y">Coronary Vessels</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071449" MajorTopicYN="N" AutoHM="Y">Proprotein Convertase 9</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IVUS</Keyword><Keyword MajorTopicYN="N">PCSK9 inhibitors</Keyword><Keyword MajorTopicYN="N">alirocumab</Keyword><Keyword MajorTopicYN="N">atorvastatin</Keyword><Keyword MajorTopicYN="N">borderline coronary lesions</Keyword><Keyword MajorTopicYN="N">coronary atherosclerosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>24</Day><Hour>2</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40702808</ArticleId><ArticleId IdType="doi">10.1177/10742484251361059</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>